Center-Authored Papers

Filters: Author is Moore, Dennis F  [Clear All Filters]
2009
Le Q-TX, Moon J, Redman MW, Williamson SK, Lara PN, Goldberg Z, Gaspar LE, Crowley J, Moore DF, Gandara DR.  2009.  Phase II study of tirapazamine, cisplatin, and etoposide and concurrent thoracic radiotherapy for limited-stage small-cell lung cancer: SWOG 0222.. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 27(18):3014-9. Abstract
2010
Zonder JA, Crowley J, Hussein MA, Bolejack V, Moore DF, Whittenberger BF, Abidi MH, Durie BGM, Barlogie B.  2010.  Lenalidomide and high-dose dexamethasone compared with dexamethasone as initial therapy for multiple myeloma: a randomized Southwest Oncology Group trial (S0232).. Blood. 116(26):5838-41. Abstract
2015
Blumenthal DT, Rankin C, Stelzer KJ, Spence AM, Sloan AE, Moore DF, Padula GDA, Schulman SB, Wade ML, Rushing EJ.  2015.  A Phase III study of radiation therapy (RT) and O(6)-benzylguanine + BCNU versus RT and BCNU alone and methylation status in newly diagnosed glioblastoma and gliosarcoma: Southwest Oncology Group (SWOG) study S0001.. International journal of clinical oncology. 20(4):650-8. Abstract
Lucas DM, Ruppert AS, Lozanski G, Dewald GW, Lozanski A, Claus R, Plass C, Flinn IW, Neuberg DS, Paietta EM et al..  2015.  Cytogenetic prioritization with inclusion of molecular markers predicts outcome in previously untreated patients with chronic lymphocytic leukemia treated with fludarabine or fludarabine plus cyclophosphamide: a long-term follow-up study of the US intergr. Leukemia & lymphoma. 56(11):3031-3037. Abstract
2016
Till BG, Li H, Bernstein SH, Fisher RI, Burack RW, Rimsza LM, Floyd JD, Dasilva MA, Moore DF, Pozdnyakova O et al..  2016.  Phase II trial of R-CHOP plus bortezomib induction therapy followed by bortezomib maintenance for newly diagnosed mantle cell lymphoma: SWOG S0601.. British journal of haematology. 172(2):208-218. Abstract
2017
West HL, Moon J, Wozniak AJ, Mack P, Hirsch FR, Bury MJ, Kwong M, Nguyen DD, Moore DF, Miao J et al..  2017.  Paired Phase II Studies of Erlotinib/Bevacizumab for Advanced Bronchioloalveolar Carcinoma or Never Smokers With Advanced Non-Small-cell Lung Cancer: SWOG S0635 and S0636 Trials.. Clinical lung cancer. Abstract